Medical Journal of Indonesia Vol. 31 No. 3 2022 FKUI
Clinical Research Factors Associated with Global Cognitive Impairment in Epilepsy Patients: A Cross-Sectional Study in Mataram, Indonesia
Dublin Core
Title
Medical Journal of Indonesia Vol. 31 No. 3 2022 FKUI
Clinical Research Factors Associated with Global Cognitive Impairment in Epilepsy Patients: A Cross-Sectional Study in Mataram, Indonesia
Clinical Research Factors Associated with Global Cognitive Impairment in Epilepsy Patients: A Cross-Sectional Study in Mataram, Indonesia
Subject
cognitive dysfunction, epilepsy, neuropsychological tests, quality of life
Description
Global cognitive impairment is an important
complication of epilepsy. The prevalence of
cognitive impairment in patients with epilepsy is
currently estimated to be 70–80%, but this can vary
by region.1,2 The number of patients with epilepsy in
developing countries tends to be higher than that of
developed countries, and only a small portion of the
patient population receives appropriate treatment;
thus, it can be estimated that the prevalence of
global cognitive impairment will be much higher in
developing countries.3,4 Our previous study in the
same population who received the conventional
antiepileptic drug (AED) monotherapy showed that
the prevalence of cognitive impairment was 75%.5
However, the prevalence of epilepsy-associated
cognitive disorders in other parts of Indonesia is
still rare. Studies conducted in Aceh and Palembang
with small sample sizes showed a prevalence of
20.6–69%.6,7 If not appropriately treated, epilepsy-
associated cognitive impairment can progress to
dementia, leading to decreased quality of life and
increased socioeconomic and health burden on their
families and the government.2
Global cognitive impairment in patients with
epilepsy can occur at the onset of epilepsy or years
after the initial diagnosis.8,9
complication of epilepsy. The prevalence of
cognitive impairment in patients with epilepsy is
currently estimated to be 70–80%, but this can vary
by region.1,2 The number of patients with epilepsy in
developing countries tends to be higher than that of
developed countries, and only a small portion of the
patient population receives appropriate treatment;
thus, it can be estimated that the prevalence of
global cognitive impairment will be much higher in
developing countries.3,4 Our previous study in the
same population who received the conventional
antiepileptic drug (AED) monotherapy showed that
the prevalence of cognitive impairment was 75%.5
However, the prevalence of epilepsy-associated
cognitive disorders in other parts of Indonesia is
still rare. Studies conducted in Aceh and Palembang
with small sample sizes showed a prevalence of
20.6–69%.6,7 If not appropriately treated, epilepsy-
associated cognitive impairment can progress to
dementia, leading to decreased quality of life and
increased socioeconomic and health burden on their
families and the government.2
Global cognitive impairment in patients with
epilepsy can occur at the onset of epilepsy or years
after the initial diagnosis.8,9
Creator
Herpan Syafii Harahap, Mohammad Rizki, Deasy Irawati
Date
October 14, 2022
Contributor
peri irawan
Format
pdf
Language
english
Type
text
Files
Citation
Herpan Syafii Harahap, Mohammad Rizki, Deasy Irawati , “Medical Journal of Indonesia Vol. 31 No. 3 2022 FKUI
Clinical Research Factors Associated with Global Cognitive Impairment in Epilepsy Patients: A Cross-Sectional Study in Mataram, Indonesia,” Repository Horizon University Indonesia, accessed September 20, 2024, https://repository.horizon.ac.id/items/show/1071.
Clinical Research Factors Associated with Global Cognitive Impairment in Epilepsy Patients: A Cross-Sectional Study in Mataram, Indonesia,” Repository Horizon University Indonesia, accessed September 20, 2024, https://repository.horizon.ac.id/items/show/1071.